Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorArrambide García, Georgina
dc.contributor.authorLlaneza González, Miguel Ángel
dc.contributor.authorFernández-Díaz, Eva
dc.contributor.authorMoreno Torres, Irene
dc.contributor.authorMeca-Lallana, Virginia
dc.contributor.authorCosta-Frossard França, Lucienne
dc.date.accessioned2022-04-06T06:38:46Z
dc.date.available2022-04-06T06:38:46Z
dc.date.issued2021-06-24
dc.identifier.citationArrambide G, Llaneza-González MA, Costa-Frossard França L, Meca-Lallana V, Díaz EF, Moreno-Torres I, et al. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry. Neurol Neuroimmunol Neuroinflamm. 2021 Jun 24;8(5):e1024.
dc.identifier.issn2332-7812
dc.identifier.urihttps://hdl.handle.net/11351/7306
dc.descriptionEsclerosi múltiple; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV
dc.description.sponsorshipThis work was funded by the Spanish Society of Neurology for the writing, editorial assistance, statistical analysis and the Article Processing Charge. Other contributions related to financial support for writing, statistical analysis, and editorial assistance were supported by Biogen, Bristol-Myers Squibb, Merck, Roche, Sanofi, and Teva.
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofseriesNeurology® neuroimmunology & neuroinflammation;8(5)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectEsclerosi múltiple - Tractament
dc.subjectMedicaments immunosupressors - Ús terapèutic - Efectes secundaris
dc.subjectCOVID-19 (Malaltia) - Epidemiologia
dc.subject.meshCoronavirus Infections
dc.subject.meshMultiple Sclerosis
dc.subject.mesh/drug therapy
dc.subject.meshImmunosuppressive Agents
dc.titleSARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1212/NXI.0000000000001024
dc.subject.decsinfecciones por Coronavirus
dc.subject.decsesclerosis múltiple
dc.subject.decs/farmacoterapia
dc.subject.decsinmunosupresores
dc.relation.publishversionhttps://doi.org/10.1212/NXI.0000000000001024
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Arrambide G] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Llaneza-González MA] Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain. [Costa-Frossard França L] Hospital Universitario Ramón y Cajal, Madrid, Spain. [Meca-Lallana V] Hospital Universitario de la Princesa, Madrid, Spain. [Díaz EF] Complejo Hospitalario Universitario de Albacete, Albacete, Spain. [Moreno-Torres I] Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
dc.identifier.pmid34168057
dc.identifier.wos000711825500024
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple